Bodybuilders and other athletes who wish to increase muscle growth use Dindolyl Methane (or DIM). Recent studies have shown that DIM could pose health hazards. For example, DIM can cause serious liver damage if consumed in excess. Another risk is kidney damage, which could lead to kidney failure. Many bodybuilders and athletes are concerned about the long-term health risks associated with DIM.
To boost testosterone production, most people take a diindolylmethane supplement. Testosterone is believed to function as an anandrogen, meaning that it can trigger hormonal changes in tissues. DIM has been shown in studies to mimic the effects of testosterone, and other hormones. Because men produce much more testosterone than women do Certain manufacturers have added diindolylmethane to their products in order to increase their competitiveness in male circles. The theory is that men respond to a product which mimics the effects of testosterone naturally produced.
Many companies advertise DIM as a tumor-suppressor. Although diindolylmethane can be effective in reducing tumor growth in laboratory animals, it was administered orally to these animals. To achieve the same result in humans, diindolylmethane would have to be consumed in high doses over a prolonged period of time. Additionally, even though the animals tested were cancer-free for a number of years but all of them suffered from liver disease at some point, possibly due to too much diindolylmethane circulating in their system. A doctor can provide you a better understanding of how DIM works within the body.
The only way to demonstrate that DIM is effective in treating breast carcinoma is to do an experiment in which cells from healthy breast cells are exposed to high doses of diindolylmethane over long periods of time. There are pros and cons to using DIM as with any chemical. The ability to mimic hormones is one of the advantages. This allows you to make insulin which can inhibit cancer cell growth. The cons include the fact diindolylmethane also produces an extremely harmful chemical known as DMSO. Read more about diindolylmethane benefits now.
One of the most commonly used claims for diindolylmethane’s use as an treatment for various ailments is that it is an anti-cancer, natural, antibacterial and anti-fungal agent. The National Institute of Health, through an exhaustive review of supportive data found no basis for these claims. According to the Institute of Chemical Technology there were no studies that supported this claim. In a thorough review of the safety characteristics of the firestone the Institute of Chemical Safety concluded that the evidence from pharmaceutical companies on the benefits to humans of diindolylmethane were not reliable.
In a May 2021 edition of the Journal of Toxicology and Environmental Health, van der Goes, and colleagues. highlighted the potential risks associated with diindolylmethane’s use, including skin rash, allergic reactions, asthma attacks, dizziness, headaches, and respiratory problems. They also noted that the recommended daily dose for this chemical is 0.2 milligrams, which is about one tenth of a teaspoon. It is unclear what the concentration is when it is compounded with other compounds. Because this substance has not been thoroughly tested, it is not considered safe at any level.
The abstract of the view suggests that the use of diindolylmethane (DIEM) in the context of treating cancer is based on the principle of inhibiting intracellular inhibition of pyruvate metabolite by flavenoids, thereby preventing accumulation of oxalates in renal tubule cells as well as adenine granulocytes. The drug metabiplicate toxicology studies have not demonstrated that this chemical is able to cause overdose. In June 1996, the Food and Drug Administration approved this drug as a prescription drug. According to the FDA the manufacturer of firestone Tincture is currently completing two major trials in Europe and the United States.
The view abstract also indicates that the use of diindolylmethane (DIEM) in the context of treating cancer is based on the principle of inhibiting intracellular inhibition of pyruvate metabolite through flavenoids, thus stopping the accumulation of oxalates within renal tubule cells and adenine granulocyte cultures. Metabiplicate toxicology studies on the drug have not shown that this chemical could cause overdose. In June 1996, the Food and Drug Administration approved the drug as a prescription drug. According to the FDA the company that makes firestone tincture is in the process of completing two major trials–one in Europe and one in the United States. According to the FDA the company that produces firestone tincture is currently in the process of finishing two major trials in Europe and one in the United States.